Drug Approval | August 17, 2021
Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site
The approval allows it to market its products in the country
The approval allows it to market its products in the country
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The facility integrates advanced scientific infrastructure and specialised workflows to support complex drug delivery systems, sterile injectables, and differentiated dosage forms
The move signals a major expansion in access to next-generation weight-loss therapies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
Subscribe To Our Newsletter & Stay Updated
